Peptide capable of inducing immune response to human gastric cancer and agent for preventing or treating human gastric cancer, containing the peptide

Abstract

A peptide that induces CTL against human gastric cancer cells is provided. A peptide having a specific amino-acid sequence and induces cytotoxic T cells that targets gastric cancer cells may be used as an agent for preventing or treating gastric cancer.

1 - 13 . (canceled)  
     
     
         14 . A vaccine for preventing or treating gastric cancer, said vaccine containing a recombinant virus or a recombinant bacterium having a DNA encoding a peptide which is a fragment of a gastric cancer antigen protein present in a human gastric cancer cell, said fragment being bound to an HLA molecule and capable of inducing a cytotoxic T cell that targets said gastric cancer cell.  
     
     
         15 . The vaccine of  claim 14 , wherein the HLA molecule is HLA-A31.  
     
     
         16 . The vaccine of  claim 14 , wherein said peptide has an amino-acid sequence represented by SEQ ID NO: 1 of the Sequence Listing.  
     
     
         17 . The vaccine of  claim 14 , wherein said peptide has an amino-acid sequence represented by SEQ ID NO: 2 of the Sequence Listing.  
     
     
         18 . A method for preventing or treating gastric cancer comprising administering to a patient in need thereof an effective amount of a peptide which is a fragment of a gastric cancer antigen protein present in a human gastric cancer cell, said fragment being bound to an HLA molecule and capable of inducing a cytotoxic T cell that targets said gastric cancer cell.  
     
     
         19 . A method for preventing or treating gastric cancer comprising administering to a patient in need thereof an effective amount of CTL which have been activated with a peptide which is a fragment of a gastric cancer antigen protein present in a human gastric cancer cell, said fragment being bound to HLA-A3 1 and capable of inducing a cytotoxic T cell that targets said gastric cancer cell; 
 wherein said peptide which is a fragment of a gastric cancer antigen protein present in a human gastric cancer cell comprises    SEQ. ID. NO. 1 and consists of 10-12 amino acid residues or    SEQ. ID. NO. 2 and consists of 9-12 amino acid residues and    wherein said CTL has been activated in vitro by adding said peptide to lymphocytes of said patient in need thereof and said administering comprises returning activated CTL to said patient in need thereof.    
     
     
         20 . A method for preventing or treating gastric cancer comprising administering to a patient in need thereof an effective amount of a vaccine containing a recombinant virus or a recombinant bacterium having a DNA encoding a peptide which is a fragment of a gastric cancer antigen protein present in a human gastric cancer cell, said fragment being bound to an HLA molecule and capable of inducing a cytotoxic T cell that targets said gastric cancer cell.  
     
     
         21 . The method of  claim 19 , wherein said peptide which is a fragment of a gastric cancer antigen protein present in a human gastric cancer cell comprises SEQ. ID. NO. 1 and consists of 10-12 amino acid residues.  
     
     
         22 . The method of  claim 19 , wherein said peptide which is a fragment of a gastric cancer antigen protein present in a human gastric cancer cell comprises SEQ. ID. NO. 2 and consists of 9-12 amino acid residues.  
     
     
         23 . The method of  claim 19 , wherein said method is for preventing gastric cancer.  
     
     
         24 . The method of  claim 19 , wherein said method is for treating gastric cancer.  
     
     
         25 . The method of  claim 19 , wherein said lymphocytes are peripheral blood lymphocytes.